Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date
European Patent Office: These 46 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "European Patent Office: These 46 Drugs Face Patent Expirations and Generic Entry From 2025 - 2026" DrugPatentWatch.com thinkBiotech, 2025 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can REZUROCK (belumosudil mesylate) generic drug versions launch?
Generic name: belumosudil mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 25, 2025
Generic Entry Controlled by: European Patent Office Patent 1,865,958
Patent Title: COMPOSES PHARMACOCINETIQUEMENT AMELIORES (PHARMACOKINETICALLY IMPROVED COMPOUNDS)
REZUROCK is a drug marketed by Kadmon Pharms Llc. There are five patents protecting this drug.
This drug has forty-nine patent family members in twenty-seven countries.
See drug price trends for REZUROCK.
The generic ingredient in REZUROCK is belumosudil mesylate. One supplier is listed for this generic product. Additional details are available on the belumosudil mesylate profile page.
When can JATENZO (testosterone undecanoate) generic drug versions launch?
Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: European Patent Office Patent 1,871,384
Patent Title: SYSTEMES D'APPORT DE SUBSTANCES PHARMACEUTIQUES DESTINES A DES MEDICAMENTS HYDROPHOBES ET COMPOSITIONS COMPRENANT CES DERNIERS (PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME)
This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO
See drug price trends for JATENZO.
The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.
When can JATENZO (testosterone undecanoate) generic drug versions launch?
Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: European Patent Office Patent 2,979,699
Patent Title: SYSTÈMES D'ADMINISTRATION PHARMACEUTIQUE POUR DES MÉDICAMENTS HYDROPHOBES ET LEURS COMPOSITIONS (PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME)
This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO
See drug price trends for JATENZO.
The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.
When can JATENZO (testosterone undecanoate) generic drug versions launch?
Generic name: testosterone undecanoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 15, 2025
Generic Entry Controlled by: European Patent Office Patent 2,985,026
Patent Title: SYSTEMES D'ADMINISTRATION PHARMACEUTIQUE POUR DES MEDICAMENTS HYDROPHOBES ET LEURS COMPOSITIONS (PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME)
This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO
See drug price trends for JATENZO.
The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.
When can TYKERB (lapatinib ditosylate) generic drug versions launch?
Generic name: lapatinib ditosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 19, 2025
Generic Entry Controlled by: European Patent Office Patent 1,871,347
Patent Title: PREPARATION PHARMACEUTIQUE (PHARMACEUTICAL COMPOSITION)
TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in twenty-six countries.
See drug price trends for TYKERB.
The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.
When can LO LOESTRIN FE (ethinyl estradiol; norethindrone acetate) generic drug versions launch?
Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: European Patent Office Patent 1,877,062
Patent Title: REGIME CONTRACEPTIF DE DOSAGE D STROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)
This drug has nine patent family members in seven countries. There has been litigation on patents covering LO LOESTRIN FE
See drug price trends for LO LOESTRIN FE.
The generic ingredient in LO LOESTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
When can LO LOESTRIN FE (ethinyl estradiol; norethindrone acetate) generic drug versions launch?
Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: European Patent Office Patent 2,305,266
Patent Title: Régime contraceptif de dosage d strogènes étendu (Extended estrogen dosing contraceptive regimen)
This drug has nine patent family members in seven countries. There has been litigation on patents covering LO LOESTRIN FE
See drug price trends for LO LOESTRIN FE.
The generic ingredient in LO LOESTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
When can LO MINASTRIN FE (ethinyl estradiol; norethindrone acetate) generic drug versions launch?
Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: European Patent Office Patent 1,877,062
Patent Title: REGIME CONTRACEPTIF DE DOSAGE D STROGENES ETENDU (EXTENDED ESTROGEN DOSING CONTRACEPTIVE REGIMEN)
LO MINASTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has nine patent family members in seven countries. There has been litigation on patents covering LO MINASTRIN FE
The generic ingredient in LO MINASTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
When can LO MINASTRIN FE (ethinyl estradiol; norethindrone acetate) generic drug versions launch?
Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: European Patent Office Patent 2,305,266
Patent Title: Régime contraceptif de dosage d strogènes étendu (Extended estrogen dosing contraceptive regimen)
LO MINASTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has nine patent family members in seven countries. There has been litigation on patents covering LO MINASTRIN FE
The generic ingredient in LO MINASTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
When can XCOPRI (cenobamate) generic drug versions launch?
Generic name: cenobamate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 22, 2025
Generic Entry Controlled by: European Patent Office Patent 1,879,873
Patent Title: COMPOSES AZOLE NEUROTHERAPEUTIQUES (NEUROTHERAPEUTIC AZOLE COMPOUNDS)
This drug has twenty-six patent family members in twenty countries.
See drug price trends for XCOPRI.
The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 1,901,729
Patent Title: FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE HDAC (PHARMACEUTICAL FORMULATIONS OF HDAC INHIBITORS)
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can BELEODAQ (belinostat) generic drug versions launch?
Generic name: belinostat
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 2,494,969
Patent Title: Formulations pharmaceutiques d'inhibiteurs de HDAC (Pharmaceutical formulations of HDAC inhibitors)
BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ
See drug price trends for BELEODAQ.
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 1,893,196
Patent Title: COMPOSE DIARYLHYDANTOINE (DIARYLHYDANTOIN COMPOUND)
XTANDI is a drug marketed by Astellas. There are five patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and ninety patent family members in thirty-five countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 2,013,187
Patent Title: COMPOSÉS DE DIARYLTHIOHYDANTOÏNE (DIARYLTHIOHYDANTOIN COMPOUNDS)
XTANDI is a drug marketed by Astellas. There are five patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and ninety patent family members in thirty-five countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 2,439,196
Patent Title: Composés de diarylthiohydantoïne destinés à être utilisés dans une méthode de traitement d'une maladie hyperproliférative (Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder)
XTANDI is a drug marketed by Astellas. There are five patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and ninety patent family members in thirty-five countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 2,444,085
Patent Title: Composés de diarylhydantoïne en tant qu'antagoniste du recepteur androgén pour le traitement du cancer (Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer)
XTANDI is a drug marketed by Astellas. There are five patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and ninety patent family members in thirty-five countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 2,561,871
Patent Title: Composés diarylhydantoines en tant qu'antagonistes du récepteur d'androgène pour le traitement du cancer (Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer)
XTANDI is a drug marketed by Astellas. There are five patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and ninety patent family members in thirty-five countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 3,020,706
Patent Title: DÉRIVÉS DE DIARYLTHIOHYDANTOÏNE UTILES POUR LE TRAITEMENT DE MALADIES HYPERPROLIFÉRATIVES (DIARYLTHIOHYDANTOIN COMPOUNDS USEFUL FOR THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER)
XTANDI is a drug marketed by Astellas. There are five patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and ninety patent family members in thirty-five countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 3,106,162
Patent Title: COMPOSES DIARYLHYDANTOINES EN TANT QU'ANTAGONISTES DU RECEPTEUR D'ANDROGENE POUR LE TRAITEMENT DU CANCER (DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER)
XTANDI is a drug marketed by Astellas. There are five patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and ninety patent family members in thirty-five countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can XTANDI (enzalutamide) generic drug versions launch?
Generic name: enzalutamide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2025
Generic Entry Controlled by: European Patent Office Patent 3,970,721
Patent Title: COMPOSÉS DIARYLHYDANTOINES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR D'ANDROGÈNE POUR LE TRAITEMENT DU CANCER (DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER)
XTANDI is a drug marketed by Astellas. There are five patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has one hundred and ninety patent family members in thirty-five countries. There has been litigation on patents covering XTANDI
See drug price trends for XTANDI.
The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.
When can TRACLEER (bosentan) generic drug versions launch?
Generic name: bosentan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 17, 2025
Generic Entry Controlled by: European Patent Office Patent 1,883,397
Patent Title: COMPRIME DISPERSIBLE (DISPERSIBLE BOSERTAN TABLET)
TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.
This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER
See drug price trends for TRACLEER.
The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.
When can LATUDA (lurasidone hydrochloride) generic drug versions launch?
Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2025
Generic Entry Controlled by: European Patent Office Patent 1,884,242
Patent Title: COMPOSITION PHARMACEUTIQUE COMPRENANT LE LURASIDONE (PHARMACEUTICAL COMPOSITION COMPRISING LURASIDONE)
This drug has fifty-eight patent family members in twenty-three countries. There has been litigation on patents covering LATUDA
See drug price trends for LATUDA.
The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.
When can LATUDA (lurasidone hydrochloride) generic drug versions launch?
Generic name: lurasidone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 26, 2025
Generic Entry Controlled by: European Patent Office Patent 2,422,783
Patent Title: Composition pharmaceutique (Pharmaceutical Composition)
This drug has fifty-eight patent family members in twenty-three countries. There has been litigation on patents covering LATUDA
See drug price trends for LATUDA.
The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.
When can VICTRELIS (boceprevir) generic drug versions launch?
Generic name: boceprevir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 02, 2025
Generic Entry Controlled by: European Patent Office Patent 1,919,478
VICTRELIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.
This drug has twenty-seven patent family members in seventeen countries.
The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.
When can OMONTYS (peginesatide acetate) generic drug versions launch?
Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 03, 2025
Generic Entry Controlled by: European Patent Office Patent 1,917,023
Patent Title: PREPARATIONS DE PEPTIDES AGONISTES DU RECEPTEUR DE L'ERYTHROPOIETINE ET UTILISATIONS (ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES)
OMONTYS is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries.
The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
When can OMONTYS (peginesatide acetate) generic drug versions launch?
Generic name: peginesatide acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 03, 2025
Generic Entry Controlled by: European Patent Office Patent 2,195,002
Patent Title: FORMULATIONS DE PEPTIDE DE RÉCEPTEUR D'ÉRYTHROPOÏÉTINE ET UTILISATIONS (ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES)
OMONTYS is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.
This drug has twenty-seven patent family members in eighteen countries.
The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.
When can SPINRAZA (nusinersen sodium) generic drug versions launch?
Generic name: nusinersen sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2025
Generic Entry Controlled by: European Patent Office Patent 1,910,395
Patent Title: Compositions et procédés de modulation de l épissage de SMN2 (Compositions and methods for modulation of SMN2 splicing)
SPINRAZA is a drug marketed by Biogen Idec. There are nine patents protecting this drug.
This drug has one hundred and two patent family members in twenty-seven countries.
See drug price trends for SPINRAZA.
The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.
When can SPINRAZA (nusinersen sodium) generic drug versions launch?
Generic name: nusinersen sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2025
Generic Entry Controlled by: European Patent Office Patent 2,548,560
Patent Title: Compositions et procédés pour modulation de l'épissage du SMN2 (Compositions and methods for modulation of SMN2 splicing)
SPINRAZA is a drug marketed by Biogen Idec. There are nine patents protecting this drug.
This drug has one hundred and two patent family members in twenty-seven countries.
See drug price trends for SPINRAZA.
The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.
When can SPINRAZA (nusinersen sodium) generic drug versions launch?
Generic name: nusinersen sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2025
Generic Entry Controlled by: European Patent Office Patent 2,644,700
Patent Title: COMPOSITIONS ET PROCÉDÉS POUR MODULATION DE L'ÉPISSAGE DU SMN2 (COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING)
SPINRAZA is a drug marketed by Biogen Idec. There are nine patents protecting this drug.
This drug has one hundred and two patent family members in twenty-seven countries.
See drug price trends for SPINRAZA.
The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.
When can SPINRAZA (nusinersen sodium) generic drug versions launch?
Generic name: nusinersen sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2025
Generic Entry Controlled by: European Patent Office Patent 3,308,788
Patent Title: COMPOSITIONS ET PROCÉDÉS POUR MODULATION DE L'ÉPISSAGE DU SMN2 (COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING)
SPINRAZA is a drug marketed by Biogen Idec. There are nine patents protecting this drug.
This drug has one hundred and two patent family members in twenty-seven countries.
See drug price trends for SPINRAZA.
The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.
When can SPINRAZA (nusinersen sodium) generic drug versions launch?
Generic name: nusinersen sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2025
Generic Entry Controlled by: European Patent Office Patent 3,470,072
Patent Title: COMPOSITIONS ET PROCÉDÉS POUR MODULATION DE L'ÉPISSAGE DU SMN2 (COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING)
SPINRAZA is a drug marketed by Biogen Idec. There are nine patents protecting this drug.
This drug has one hundred and two patent family members in twenty-seven countries.
See drug price trends for SPINRAZA.
The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: European Patent Office Patent 1,896,002
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries.
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: European Patent Office Patent 2,032,124
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries.
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: European Patent Office Patent 2,185,139
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries.
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: European Patent Office Patent 2,214,650
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries.
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: European Patent Office Patent 2,474,308
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries.
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can APLENZIN (bupropion hydrobromide) generic drug versions launch?
Generic name: bupropion hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 27, 2025
Generic Entry Controlled by: European Patent Office Patent 2,502,621
APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has fifty-two patent family members in eighteen countries.
See drug price trends for APLENZIN.
The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.
When can BOSULIF (bosutinib monohydrate) generic drug versions launch?
Generic name: bosutinib monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 01, 2025
Generic Entry Controlled by: European Patent Office Patent 1,902,029
BOSULIF is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF
See drug price trends for BOSULIF.
The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.
When can DUEXIS (famotidine; ibuprofen) generic drug versions launch?
Generic name: famotidine; ibuprofen
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 18, 2025
Generic Entry Controlled by: European Patent Office Patent 1,919,288
Patent Title: MEDICAMENTS CONTENANT FAMOTIDINE ET IBUPROFENE, ET ADMINISTRATION DESDITS MEDICAMENTS (MEDICAMENTS CONTAINING FAMOTIDINE AND IBUPROFEN AND ADMINISTRATION OF SAME)
This drug has twenty-five patent family members in fifteen countries. There has been litigation on patents covering DUEXIS
See drug price trends for DUEXIS.
The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the famotidine; ibuprofen profile page.
When can DUEXIS (famotidine; ibuprofen) generic drug versions launch?
Generic name: famotidine; ibuprofen
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 18, 2025
Generic Entry Controlled by: European Patent Office Patent 2,043,637
Patent Title: PROCÉDÉS ET MÉDICAMENTS DESTINÉS À L'ADMINISTRATION D'IBUPROFÈNE (METHODS AND MEDICAMENTS FOR ADMINISTRATION OF IBUPROFEN)
This drug has twenty-five patent family members in fifteen countries. There has been litigation on patents covering DUEXIS
See drug price trends for DUEXIS.
The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the famotidine; ibuprofen profile page.
When can DUEXIS (famotidine; ibuprofen) generic drug versions launch?
Generic name: famotidine; ibuprofen
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 18, 2025
Generic Entry Controlled by: European Patent Office Patent 2,438,919
Patent Title: Compositions contenant de l'ibuprofene et de la famotidine ainsi que des compositions contenant de 25 mg a 28 mg de la famotidine (Compositions comprising famotidine and ibuprofen as well as compositions comprising 25 mg to 28 mg famotidine)
This drug has twenty-five patent family members in fifteen countries. There has been litigation on patents covering DUEXIS
See drug price trends for DUEXIS.
The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this API. Eleven suppliers are listed for this generic product. Additional details are available on the famotidine; ibuprofen profile page.
When can APTIOM (eslicarbazepine acetate) generic drug versions launch?
Generic name: eslicarbazepine acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: European Patent Office Patent 1,915,346
Patent Title: REDUCTION CATALYTIQUE ASYMETRIQUE D'OXCARBAZEPINE (ASYMMETRIC CATALYTIC REDUCTION OF OXCARBAZEPINE)
This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering APTIOM
See drug price trends for APTIOM.
The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.
When can APTIOM (eslicarbazepine acetate) generic drug versions launch?
Generic name: eslicarbazepine acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: European Patent Office Patent 2,319,836
Patent Title: Reduction catalytique asymetrique d'oxcarbazepine (Asymmetric catalytic reduction of oxcarbazepine)
This drug has one hundred patent family members in twenty-six countries. There has been litigation on patents covering APTIOM
See drug price trends for APTIOM.
The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: European Patent Office Patent 1,912,999
Patent Title: INHIBITEURS MACROCYCLIQUES DU VIRUS DE L'HÉPATITE C (MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS)
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and forty patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: European Patent Office Patent 2,322,516
Patent Title: Composés intermédiaires pour la préparation d'inhibiteurs macrocycliques du virus de l'hépatite C (Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus)
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and forty patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can OLYSIO (simeprevir sodium) generic drug versions launch?
Generic name: simeprevir sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 29, 2025
Generic Entry Controlled by: European Patent Office Patent 2,937,339
Patent Title: Inhibiteurs macrocycliques du virus de l'hépatite C (Macrocylic inhibitors of hepatitis c virus)
OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.
This drug has one hundred and forty patent family members in forty-three countries.
See drug price trends for OLYSIO.
The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 02, 2025
Generic Entry Controlled by: European Patent Office Patent 1,919,606
Patent Title: REVETEMENT PAR UN OXYDE METALLIQUE D'INGREDIENTS HYDROINSOLUBLES (METAL OXIDE COATING OF WATER INSOLUBLE INGREDIENTS)
EPSOLAY is a drug marketed by Galderma Labs Lp. There are eleven patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has forty-five patent family members in thirteen countries.
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the benzoyl peroxide profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 02, 2025
Generic Entry Controlled by: European Patent Office Patent 2,431,088
Patent Title: Revêtement d'oxyde métallique d'ingrédients insolubles dans l'eau (Metal oxide coating of water insoluble ingredients)
EPSOLAY is a drug marketed by Galderma Labs Lp. There are eleven patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has forty-five patent family members in thirteen countries.
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the benzoyl peroxide profile page.
When can EPSOLAY (benzoyl peroxide) generic drug versions launch?
Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 02, 2025
Generic Entry Controlled by: European Patent Office Patent 2,431,089
Patent Title: Revêtement d'oxyde métallique d'ingrédients insolubles dans l'eau (Metal oxide coating of water insoluble ingredients)
EPSOLAY is a drug marketed by Galderma Labs Lp. There are eleven patents protecting this drug. One tentatively approved generic is ready to enter the market.
This drug has forty-five patent family members in thirteen countries.
See drug price trends for EPSOLAY.
The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the benzoyl peroxide profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2025
Generic Entry Controlled by: European Patent Office Patent 1,931,316
Patent Title: COMPOSITIONS PHARMACEUTIQUES A LIBERATION CONTROLEE DESTINEES A DES MEDICAMENTS ACIDO-LABILES (CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGS)
CREON is a drug marketed by
This drug has forty-five patent family members in thirteen countries. There has been litigation on patents covering CREON
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can CREON (pancrelipase (amylase;lipase;protease)) generic drug versions launch?
Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 15, 2025
Generic Entry Controlled by: European Patent Office Patent 1,931,317
Patent Title: MICROGRANULES DE PANCREATINE ADAPTES A UN ENROBAGE ENTERIQUE (PANCREATIN MICROPELLETS SUITABLE FOR ENTERIC COATING)
CREON is a drug marketed by
This drug has forty-five patent family members in thirteen countries. There has been litigation on patents covering CREON
See drug price trends for CREON.
The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.
When can JYNARQUE (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: European Patent Office Patent 1,919,874
Patent Title: PROCEDE DE PREPARATION DE COMPOSES DE BENZAZEPINE OU DE SELS DESDITS COMPOSES (PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF)
JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE
See drug price trends for JYNARQUE.
The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can JYNARQUE (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: European Patent Office Patent 2,251,319
Patent Title: Procédés pour préparer des dérivés d' acide benzoïque (Process for preparing derivatives of benzoic acid)
JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE
See drug price trends for JYNARQUE.
The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can JYNARQUE (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: European Patent Office Patent 2,261,215
Patent Title: Procédé de préparation de composés de benzazépine ou de leurs sels (Process for preparing benzazepine compounds or salts thereof)
JYNARQUE is a drug marketed by Otsuka. There are two patents protecting this drug.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering JYNARQUE
See drug price trends for JYNARQUE.
The generic ingredient in JYNARQUE is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can SAMSCA (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: European Patent Office Patent 1,919,874
Patent Title: PROCEDE DE PREPARATION DE COMPOSES DE BENZAZEPINE OU DE SELS DESDITS COMPOSES (PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF)
SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA
See drug price trends for SAMSCA.
The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can SAMSCA (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: European Patent Office Patent 2,251,319
Patent Title: Procédés pour préparer des dérivés d' acide benzoïque (Process for preparing derivatives of benzoic acid)
SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA
See drug price trends for SAMSCA.
The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can SAMSCA (tolvaptan) generic drug versions launch?
Generic name: tolvaptan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 02, 2025
Generic Entry Controlled by: European Patent Office Patent 2,261,215
Patent Title: Procédé de préparation de composés de benzazépine ou de leurs sels (Process for preparing benzazepine compounds or salts thereof)
SAMSCA is a drug marketed by Otsuka. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has eighty-six patent family members in twenty-four countries. There has been litigation on patents covering SAMSCA
See drug price trends for SAMSCA.
The generic ingredient in SAMSCA is tolvaptan. There are eight drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the tolvaptan profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2025
Generic Entry Controlled by: European Patent Office Patent 1,940,364
Patent Title: CAPSULES DE PIRFENIDONE ET EXCIPIENTS PHARMACOCOMPATIBLES (CAPSULE FORMULATION OF PIRFENIDONE AND PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS)
ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-four patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ESBRIET (pirfenidone) generic drug versions launch?
Generic name: pirfenidone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2025
Generic Entry Controlled by: European Patent Office Patent 2,431,025
Patent Title: Formulation de capsule de pirfénidone et excipients pharmaceutiquement acceptables (Capsule formulation of pirfenidone and pharmaceutically acceptable excipients)
ESBRIET is a drug marketed by Genentech Inc. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.
This drug has two hundred and sixty-four patent family members in forty-six countries. There has been litigation on patents covering ESBRIET
See drug price trends for ESBRIET.
The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-two suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.
When can ZUNVEYL (benzgalantamine gluconate) generic drug versions launch?
Generic name: benzgalantamine gluconate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2025
Generic Entry Controlled by: European Patent Office Patent 1,777,222
Patent Title: Inhibiteurs de la cholinesterase avec une perméabilité améliorée de la barrière ématoencéphalique pour le traitement de troubles cognitifs (Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment)
ZUNVEYL is a drug marketed by Alpha Cognition. There are two patents protecting this drug.
This drug has twenty-four patent family members in seventeen countries.
The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.
When can ZUNVEYL (benzgalantamine gluconate) generic drug versions launch?
Generic name: benzgalantamine gluconate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 22, 2025
Generic Entry Controlled by: European Patent Office Patent 1,940,817
Patent Title: AMPLIFICATEURS CHOLINERGIQUES DE PERMÉABILITÉ DE LA BARRIÈRE SANG-CERVEAU AMÉLIORÉE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNÉES D'UNE DÉFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT)
ZUNVEYL is a drug marketed by Alpha Cognition. There are two patents protecting this drug.
This drug has twenty-four patent family members in seventeen countries.
The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.
When can VARITHENA (polidocanol) generic drug versions launch?
Generic name: polidocanol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 21, 2025
Generic Entry Controlled by: European Patent Office Patent 1,945,533
Patent Title: VALVE POUR AEROSOL (AEROSOL VALVE)
VARITHENA is a drug marketed by Provensis. There are two patents protecting this drug.
This drug has thirty-one patent family members in eighteen countries.
See drug price trends for VARITHENA.
The generic ingredient in VARITHENA is polidocanol. Two suppliers are listed for this generic product. Additional details are available on the polidocanol profile page.
When can LYRICA CR (pregabalin) generic drug versions launch?
Generic name: pregabalin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 02, 2025
Generic Entry Controlled by: European Patent Office Patent 1,945,186
Patent Title: COMPOSITIONS PHARMACEUTIQUES SOLIDES ORALES ADAPTEES A UNE SEULE PRISE PAR JOUR, CONTENANT LA PREGABALINE, UN AGENT MATRICIEL AINSI QU'UN AGENT GONFLANT (SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ONCE DAILY DOSING CONTAINING PREGABALIN, A MATRIX FORMING AGENT AND A SWELLING AGENT)
This drug has thirty-seven patent family members in thirty-three countries.
See drug price trends for LYRICA CR.
The generic ingredient in LYRICA CR is pregabalin. There are forty-one drug master file entries for this API. Fifty-six suppliers are listed for this generic product. Additional details are available on the pregabalin profile page.
When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch?
Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 09, 2025
Generic Entry Controlled by: European Patent Office Patent 1,948,158
Patent Title: COMBINAISON PHARMACEUTIQUES D'UN ANTAGONISTE DE RECEPTEUR D'ANGIOTENSINE ET D'UN INHIBITEUR DE NEP (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)
ENTRESTO SPRINKLE is a drug marketed by Novartis. There are four patents protecting this drug.
This drug has one hundred and twenty-eight patent family members in forty countries. There has been litigation on patents covering ENTRESTO SPRINKLE
The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.
When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch?
Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 09, 2025
Generic Entry Controlled by: European Patent Office Patent 2,340,828
Patent Title: Combinaisons pharmaceutiques d'un antagoniste de récepteur de l'angiotensine et inhibiteurs de nep (PHARMACEUTICAL COMBINATIONS OF AN ANGIOTENSIN RECEPTOR ANTAGONIST AND AN NEP INHIBITOR)
ENTRESTO SPRINKLE is a drug marketed by Novartis. There are four patents protecting this drug.
This drug has one hundred and twenty-eight patent family members in forty countries. There has been litigation on patents covering ENTRESTO SPRINKLE
The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.
When can ENTRESTO SPRINKLE (sacubitril; valsartan) generic drug versions launch?
Generic name: sacubitril; valsartan
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 09, 2025
Generic Entry Controlled by: European Patent Office Patent 3,685,833
Patent Title: COMPOSÉ COMPRENANT UN ARB ET UN NEPI (COMPOUND COMPRISING AN ARB AND A NEPI)
ENTRESTO SPRINKLE is a drug marketed by Novartis. There are four patents protecting this drug.
This drug has one hundred and twenty-eight patent family members in forty countries. There has been litigation on patents covering ENTRESTO SPRINKLE
The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.
When can ZTALMY (ganaxolone) generic drug versions launch?
Generic name: ganaxolone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2025
Generic Entry Controlled by: European Patent Office Patent 1,959,966
Patent Title: FORMES GALÉNIQUES DE GANAXOLONE ET PROCÉDÉS DE PREPARATION ET D'UTILISATION DE CELLES-CI (GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF)
ZTALMY is a drug marketed by Marinus. There are nine patents protecting this drug.
This drug has forty-five patent family members in sixteen countries.
See drug price trends for ZTALMY.
The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.
When can AXUMIN (fluciclovine f-18) generic drug versions launch?
Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 29, 2025
Generic Entry Controlled by: European Patent Office Patent 1,978,015
Patent Title: COMPOSE PRECURSEUR DE COMPOSE ORGANIQUE MARQUE A L'HALOGENE RADIOACTIF (PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN LABELED ORGANIC COMPOUND)
AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.
This drug has thirty patent family members in sixteen countries.
The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.
When can AXUMIN (fluciclovine f-18) generic drug versions launch?
Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 29, 2025
Generic Entry Controlled by: European Patent Office Patent 3,354,639
Patent Title: COMPOSÉ PRÉCURSEUR DE COMPOSÉ ORGANIQUE MARQUÉ PAR UN ATOME D'HALOGÈNE RADIOACTIF (PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUND)
AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.
This drug has thirty patent family members in sixteen countries.
The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.
When can XALKORI (crizotinib) generic drug versions launch?
Generic name: crizotinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2025
Generic Entry Controlled by: European Patent Office Patent 1,963,302
Patent Title: POLYMORPHES D'UN INHIBITEUR DE C-MET/HGFR (POLYMORPHS OF A C-MET/HGFR INHIBITOR)
XALKORI is a drug marketed by Pf Prism Cv. There are five patents protecting this drug.
This drug has one hundred and fifty-two patent family members in forty-eight countries.
See drug price trends for XALKORI.
The generic ingredient in XALKORI is crizotinib. One supplier is listed for this generic product. Additional details are available on the crizotinib profile page.
When can BUNAVAIL (buprenorphine hydrochloride; naloxone hydrochloride) generic drug versions launch?
Generic name: buprenorphine hydrochloride; naloxone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 13, 2025
Generic Entry Controlled by: European Patent Office Patent 1,968,539
Patent Title: DISPOSITIF RESISTANT AUX ABUS POUR L'ADMINISTRATION TRANSMUCOSALE DE MEDICAMENTS (ABUSE RESISTANT TRANSMUCOSAL DRUG DELIVERY DEVICE)
This drug has eighty-three patent family members in twenty-six countries. There has been litigation on patents covering BUNAVAIL
See drug price trends for BUNAVAIL.
The generic ingredient in BUNAVAIL is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 16, 2025
Generic Entry Controlled by: European Patent Office Patent 1,988,877
Patent Title: COMPOSITIONS THERAPEUTIQUES COMPRENANT DE L'INGÉNOL-3-ANGELATE (THERAPEUTIC COMPOSITIONS COMPRISING INGENOL-3-ANGELATE)
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can PICATO (ingenol mebutate) generic drug versions launch?
Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 16, 2025
Generic Entry Controlled by: European Patent Office Patent 2,399,571
Patent Title: Compositions thérapeutiques comprenant de l'ingénol-2-angelate (Therapeutic compositions comprising ingenol-3-angelate)
This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO
See drug price trends for PICATO.
The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.
When can KOSELUGO (selumetinib sulfate) generic drug versions launch?
Generic name: selumetinib sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 21, 2025
Generic Entry Controlled by: European Patent Office Patent 1,968,948
Patent Title: NOUVEAU SEL HYDROGENOSULFATE (NOVEL HYDROGEN SULFATE SALT)
KOSELUGO is a drug marketed by Astrazeneca. There are five patents protecting this drug.
This drug has one hundred and ninety-eight patent family members in forty-four countries.
See drug price trends for KOSELUGO.
The generic ingredient in KOSELUGO is selumetinib sulfate. One supplier is listed for this generic product. Additional details are available on the selumetinib sulfate profile page.
When can CAMCEVI KIT (leuprolide mesylate) generic drug versions launch?
Generic name: leuprolide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 18, 2026
Generic Entry Controlled by: European Patent Office Patent 1,984,009
Patent Title: COMPOSITIONS PHARMACEUTIQUES A STABILITE AMELIOREE (PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY)
CAMCEVI KIT is a drug marketed by Accord. There are five patents protecting this drug.
This drug has thirty-nine patent family members in nineteen countries.
The generic ingredient in CAMCEVI KIT is leuprolide mesylate. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the leuprolide mesylate profile page.
When can AMITIZA (lubiprostone) generic drug versions launch?
Generic name: lubiprostone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 24, 2026
Generic Entry Controlled by: European Patent Office Patent 1,978,944
Patent Title: FORMULATION DE CAPSULE GELATINEUSE MOLLE (SOFT-GELATIN CAPSULE FORMULATION)
This drug has forty-nine patent family members in nineteen countries. There has been litigation on patents covering AMITIZA
See drug price trends for AMITIZA.
The generic ingredient in AMITIZA is lubiprostone. There are ten drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the lubiprostone profile page.
When can LEXISCAN (regadenoson) generic drug versions launch?
Generic name: regadenoson
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 03, 2026
Generic Entry Controlled by: European Patent Office Patent 1,989,214
Patent Title: PROCEDE DE PREPARATION D'UN AGONISTE DE RECEPTEUR A2A-ADENOSINE ET SES POLYMORPHES (PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS)
LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in eighteen countries. There has been litigation on patents covering LEXISCAN
See drug price trends for LEXISCAN.
The generic ingredient in LEXISCAN is regadenoson. There are nine drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the regadenoson profile page.
When can LEXISCAN (regadenoson) generic drug versions launch?
Generic name: regadenoson
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 03, 2026
Generic Entry Controlled by: European Patent Office Patent 2,581,381
Patent Title: Procédé de préparation d'un agoniste du récepteur A2A-adénosine et ses polymorphes (Process for preparing an A2A-adenosine receptor agonist and its polymorphs)
LEXISCAN is a drug marketed by Astellas. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-eight patent family members in eighteen countries. There has been litigation on patents covering LEXISCAN
See drug price trends for LEXISCAN.
The generic ingredient in LEXISCAN is regadenoson. There are nine drug master file entries for this API. Fifteen suppliers are listed for this generic product. Additional details are available on the regadenoson profile page.
When can RAPIVAB (peramivir) generic drug versions launch?
Generic name: peramivir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2026
Generic Entry Controlled by: European Patent Office Patent 1,986,626
Patent Title: TRAITEMENTS ANTIVIRAUX INTRAVEINEUX (INTRAVENOUS ANTIVIRAL TREATMENTS)
RAPIVAB is a drug marketed by Biocryst. There are two patents protecting this drug.
This drug has forty-two patent family members in fourteen countries.
See drug price trends for RAPIVAB.
The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.
When can MACRILEN (macimorelin acetate) generic drug versions launch?
Generic name: macimorelin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 18, 2026
Generic Entry Controlled by: European Patent Office Patent 1,984,744
Patent Title: METHODES ET KITS PERMETTANT DE DIAGNOSTIQUER UNE CARENCE EN HORMONE DE CROISSANCE (METHODS AND KITS TO DIAGNOSE GROWTH HORMONE DEFICIENCY)
MACRILEN is a drug marketed by Novo. There is one patent protecting this drug.
This drug has eleven patent family members in ten countries.
See drug price trends for MACRILEN.
The generic ingredient in MACRILEN is macimorelin acetate. One supplier is listed for this generic product. Additional details are available on the macimorelin acetate profile page.
When can PRESTALIA (amlodipine besylate; perindopril arginine) generic drug versions launch?
Generic name: amlodipine besylate; perindopril arginine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 28, 2026
Generic Entry Controlled by: European Patent Office Patent 1,989,182
PRESTALIA is a drug marketed by Adhera. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty patent family members in twenty-seven countries. There has been litigation on patents covering PRESTALIA
The generic ingredient in PRESTALIA is amlodipine besylate; perindopril arginine. There are fifty drug master file entries for this API. Additional details are available on the amlodipine besylate; perindopril arginine profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch?
Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2026
Generic Entry Controlled by: European Patent Office Patent 2,018,160
Patent Title: FORMULATIONS A LIBERATION MODIFIEE CONTENANT DES COMPLEXES MEDICAMENT - RESINE ECHANGEUSE D'IONS (MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES)
This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR
See drug price trends for DYANAVEL XR.
The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the amphetamine profile page.
When can DYANAVEL XR (amphetamine) generic drug versions launch?
Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2026
Generic Entry Controlled by: European Patent Office Patent 2,428,205
Patent Title: Formulations à libération modifiée contenant des complexes médicament - résine échangeuse d'ions (Modified release formulations containing drug-ion exchange resin complexes)